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Comparison of the Effectiveness of
Embolic Agents for Bronchial Artery
Embolization: Gelfoam versus Polyvinyl
Alcohol
Objective: The purpose of this study was to compare the results of different
agents for bronchial artery embolization of hemoptysis.
Materials and Methods: From March 1992 to December 2006, a bronchial
artery embolization was performed on 430 patients with hemoptysis. The patients
were divided into three groups. Group 1 included 74 patients treated with a
gelfoam particle (1×1×1 mm), while group 2 comprised of 205 patients treated
with polyvinyl alcohol (PVA) at 355-500 μ m, and group 3 included 151 patients
treated with PVA at 500-710 μ m. We categorized the results as technical and
clinical successes, and also included the mid-term results. Retrospectively, the
technical success was compared immediately after the procedure. The clinical
success and mid-term results (percentage of patients who were free of hemopty-
sis) were compared at 1 and 12 months after the procedure, respectively. 
Results: Neither the technical successes (group 1; 85%, 2; 85%, 3; 90%) nor
the clinical successes (group 1; 72%, 2; 74%, 3; 71%) showed a significant differ-
ence among the 3 groups (p > 0.05). However, the mid-term results (group 1;
45%, 2; 63%, 3; 62%) and mid-term results excluding the recurrence from collat-
eral vessels in each of the groups (group 1; 1 patient, 2; 4 patients, 3; 2 patients)
showed that group 1 was lower than the other two groups (p < 0.05). No signifi-
cant difference was discovered for the mid-term results between groups 2 and 3.
Moreover, the same results not including incidences of recurrence from collateral
vessels also showed no statistical significance between the two groups (p >
0.05).
Conclusion: Polyvinyl alcohol appears to be the more optimal modality com-
pared to gelfoam particle for bronchial artery embolization in order to improve the
mid-term results. The material size of PVA needs to be selected to match with the
vascular diameter.
emoptysis is a manifestation of pulmonary or tracheobronchial disease (1,
2). It is caused by chronic lung diseases such as pulmonary tuberculosis,
chronic bronchitis, bronchiectasis, lung cancer, aspergillosis, and pneumo-
coniosis. In most cases, the amount of hemoptysis is small, and it subsides gradually
without a need for treatment.  
However, massive hemoptysis, defined as 300 to 600 ml per 24 hours, is a life-
threatening condition with a reported mortality rate of 50 to 60% (1).
Bronchial artery embolization (BAE) has been proven as a good treatment method
for a patient for whom a surgical procedure is not an option as well as for a patient
needing palliative therapy requiring hemodynamic stabilization (2). However, 36 to
44% of patients who underwent successful BAE for hemoptysis reported recurrences
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Hduring long-term follow-up (1, 2). Many studies have dealt
with causes for the recurrence of hemoptysis, as well as
underlying diseases or angiographic findings have been
identified as the reasons (2-5). Nevertheless, a number of
studies focused on embolic agents that have been relatively
small and have consequently generated much debate.
The purpose of this study is to compare results of various
embolic agents used in our hospital to treat hemoptysis and
to select an embolic agent resulting in a more favorable
outcome.  
MATERIALS AND METHODS
Because this study was retrospective, Institutional
Review Board approval was not required. Prior to the
procedure, written informed consent was obtained, in
accordance with the Institutional Review Board policy. 
From March 1992 to December 2006, 561 patients
underwent BAE to treat hemoptysis in our hospital. Of
these patients, 430 patients consisting of 246 males and
184 females ranging in age from 18 to 87 years old (mean
age 56.7 years) were selected for the study by exclusion
criteria. The exclusion criteria were the following: (i) no
angiographic finding of hemoptysis on diagnostic bronchial
angiography, (ii) embolization by other than gelfoam and
PVA or by a combination of more than two embolic
agents, (iii) loss during follow-up or inability to confirm
recurrence of hemoptysis during 12 months after BAE. 
Then, according to the embolic agents used, patients
were divided into three groups: group 1 - BAE was
performed with the SPONGOSTAN Standard gelfoam
particle (1×1×1 mm) (Johnson & Johnson MEDICAL
limited, Skipton, UK), group 2 - BAE was performed with
Contour Emboli PVA (355-500 μ m) (Boston Scientific,
Natick, MA), and group 3 - BAE was performed with
Contour Emboli PVA (500-710 μ m) (Boston Scientific,
Natick, MA).
Group 1 had 74 patients, of whom 44 had hemoptysis
due to pulmonary tuberculosis, 18 had bronchiectasis, five
had lung cancer, and seven had other diseases (3 with
pneumonia, 2 with lung abscesses, and 2 with pulmonary
infarction). Group 2 consisted of 205 patients, of whom
148 had pulmonary tuberculosis, 38 had bronchiectasis, 13
had lung cancer, and six had other diseases (2 with
pneumonia, 3 with lung abscesses, and 1 with coagulopa-
thy due to coumadin medication). Among 151 patients in
group 3, 94 had pulmonary tuberculosis as the cause of
hemoptysis, 36 had bronchiectasis, 14 had lung cancer, and
seven had other diseases (4 with pneumonia, 1 with a lung
abscess, 1 with coagulopathy due to coumadin medication,
and 1 with pulmonary infarction) (Table 1).
To detect bleeding sites prior to BAE, all the patients
with hemoptysis underwent chest CT or bronchoscopy,
and a diagnostic angiography was performed to confirm
the bleeding site. Using the standard Seldinger technique,
selective bronchial angiography was performed using a
number of different 5-Fr catheters such as G.R.B & G.L.B
(JUNG SUNG MEDICAL Co., Ltd., Seongnam, Korea) or
Cobra (TERUMO
�, Tokyo, Japan) to localize the site. In
some cases from each group, there were bleeding sites of
transpleural supplies from subclavian branches which
included the internal mammary artery, lateral thoracic
artery or other branches, bronchial arteries originating
from the intercostobronchial trunk (31 patients in group 1,
71 patients in group 2, and 59 patients in group 3) (Fig. 1),
or in some cases the anterior spinal artery was seen on
angiography (2 patients in group 1, 3 patients in group 2,
and 2 patients in group 3). The bleeding vessels were
picked using 2 or 2.5 Fr Renegade (Boston scientific,
Natick, USA) or Progreat
TM (TERUMO
�, Tokyo, Japan)
microcatheters. We guided all vessels before the emboliza-
tion, and any findings of hypervascularization, arterial
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Table 1. Underlying Diseases of Each Group
Group 1 Group 2 Group 3
Pulmonary tuberculosis 44 (60%) 148 (72%) 94 (62%)
Bronchiectasis 18 (24%) 038 (19%) 36 (24%)
Lung cancer 5 (7%) 013 (6%)0 14 (9%)0
Others
� 7 (9%) 06 (3%) 7 (5%)
Note.─
�Others include lung abscesses, coagulopathy, pulmonary 
infarction, and pneumonia.
Table 2. Clinical Data, Number of Embolized Artery, and
Angiographic Findings According to Groups 
Group 1 Group 2 Group 3
Age in years 
(mean ± SD)
57.5±16.10 65.6±18.15 59.7±15.34
Extent of bleeding (%)
Massive
� 26 (36) 076 (37) 055 (37)
Moderate 48 (64) 129 (63) 096 (64)
Number of embolized artery (%)
Single 10 (14) 035 (17) 021 (14)
Two 14 (19) 048 (23) 027 (18)
More than three 50 (68) 122 (60) 103 (68)
Angiographic finding (%)
Hypervascularization 0.74 (100).0 . 205 (100).0 . 151 (100).
Arterial enlargement 68 (92) 175 (85) 140 (93)
Systemic to 
pulmonary shunt
21 (28) 068 (33)
0
44 (29)
Extravasation 10 (14) 038 (19) 027 (18)
Note.─
�Massive hemoptysis is defined as 300 to 600 ml or more of 
blood loss from hemoptysis over 24 hour period.enlargement, bronchial-pulmonary artery shunt, and
extravasation for contrast material obtained from angiog-
raphy were considered as evidence of the bleeding (Table
2). In addition, closed fluoroscopic observation was
performed during the embolization to prevent other
complications such as reflux into the anterior spinal artery.
In each procedure, BAE was performed until the bleeding
sites were no longer visible. Images from the arterial
embolizations were captured by the Optimus DVI System
and BV 5000 (Philips Healthcare, Best, The Netherlands).
Investigations of underlying diseases, embolic agents,
and follow-ups were conducted by reviewing patient
medical records or by telephone interview. If medical
records indicated recurrence of hemoptysis, follow-ups
were then terminated. Also, observations were concluded
when no recurrence was observed within 12 months after
BAE. 
We defined technical success as a percentage of patients
without a recurrence immediately after BAE. Clinical
success was defined as a percentage of patients who
hemoptysis-free for at least one month after the emboliza-
tion, and the mid-term result was set as a percentage of
patients who were free of hemoptysis 12 months after the
procedure (6). Next, we assessed cumulative hemoptysis-
free rates using the Cutler-Ederer method with SPSS
version 12.0 (SPSS, Chicago, IL). P-values less than 0.05
were set as the threshold for statistical significance. 
RESULTS
In group 1, 11 patients showed recurrence immediately
after the BAE, and the technical success was 85% (63 of
74). After one month, 10 patients had recurrence in
previously embolized vessels without collateral vessel
origin, and the clinical success was 72% (53 of 74).
Recurrence after 12 months was found in 20 patients, and
the mid-term result was found to be 45% (33 of 74).
Among them, 19 experienced recurrences in previously
embolized vessels, while one was due to collateral
bleeding.
In group 2, 30 patients showed hemoptysis immediately
after the procedure, and  technical success was calculated
to be 85% (175 of 205). After one month, 23 patients
experienced recurrence due to recanalization, and the
clinical success was 74% (152 of 205). There was no
bleeding focus in collaterals after one month; however,
after 12 months, 22 patients had experienced a recurrence,
and the mid-term result was 63% (130 of 205). Recurrence
in previously embolized vessel was found in 18 patients, of
whom four had collateral vessels.
In group 3, 15 patients showed recurrence of hemoptysis
immediately after the procedure. As a result, the technical
success rate was 90% (136 of 151). Recurrence occurred in
29 patients, in previously embolized vessels, and they had
no collateral recurrence after one month. Hence, the
clinical success was 71% (107 of 151) for group 3. After 12
months, a total of 13 patients had recurrence. Of these, 11
originated from the embolized vessels, whereas two
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Fig. 1. 39-year-old male with hemoptysis in right lower lobe. 
A. Bronchial angiography showed bleeding from right bronchial artery which originated from intercostobronchial trunk. 
B. After embolization with 2-Fr microcatheter, follow-up bronchial angiography showed no evidence of bleeding in right bronchial artery.
ABoriginated from collateral vessels. The mid-term result was
found to be 62% (94 of 151) (Table 3) (Fig. 2).
There were no significant differences among the three
groups for the technical and clinical success rates (p >
0.05). However, group 1 showed a significantly lower mid-
term result than the other groups. Significant differences
for the mid-term results were found between groups 1 and
2 (p = 0.02) as well as groups 1 and 3 (p = 0.03). 
Furthermore, for the mid-term results, when subtracting
incidences of recurrence from collateral vessels in each
group (group 1: 32 of 74, group 2: 126 of 205, group 3: 92
of 151), we found that group 1 also showed a significantly
lower result than the other two groups (between groups 1
and 2: p = 0.03 and between groups 1 and 3: p = 0.04).  
There were similar rates of technical failures among the
three groups (group 1: 15%, group 2: 15%, group 3:
10%), and there had been no major procedure-related
complications including spinal cord ischemia, non-target
organ embolization, dysphagia, and so on.
DISCUSSION
From the moment Remy et al. (7) first performed BAE to
treat hemoptysis, BAE has been used to treat both massive
and chronic intermittent hemoptysis (8). BAE has also
been used as a preoperative method to improve the lung
function of patients prior to a surgery, and it is an effective
hemostatic treatment modality in patients for whom
surgery is not an option (7-10).
Therapeutic benefits of BAE in hemoptysis are diverse
depending on the amount of bleeding, risk of recurrent
hemoptysis, and overall lung function of patients (8).
Among them, the risk of recurrent hemoptysis is a more
important factor, especially in long-term recurrence.
Moreover, the status of underlying diseases and character-
istics of embolic agents may affect the risk of recurrent
hemoptysis (6, 11). 
Many embolic agents are used to perform BAE to treat
hemoptysis, which include gelfoam and PVA. Each
material has its own advantages and disadvantages.
Gelfoam is cost-effective, and the size can be controlled.
However, recanalization can occur faster than PVA,
because gelfoam is absorbed spontaneously. PVA is a
permanent material and can occlude a vessel at the small
arteriolar level, but it results in collateral flow (12, 13). 
In this study, we compared the relationship between
clinical outcomes and embolic agents, especially PVA and
gelfoam. We found that there was no significant difference
in the results found among gelfoam and two PVA groups
immediately after the procedure and after one month.
However, PVA had better results than gelfoam after 12
months, regardless of particle size. No difference was
found among these groups immediately after the emboliza-
tion, which means that there was no difference in the rate
of technical failure. Causes of technical failure include
overlooking other bleeding sites, incomplete embolization,
and so on (14). No significant difference was noted after
one month also means that there was no difference in the
temporary effect of BAE among the three embolic agent
groups. However, a significant difference was found after
12 months; PVA had a better outcome than gelfoam in a
setting of minimal progression of underlying diseases.
Many studies have dealt with the relationship between
recurrent hemoptysis and embolic materials. However,
they presented a controversy about which of gelfoam or
PVA was the more effective embolic agent (15, 16).
According to the report by Chung et al. (17), if an initially
successful embolization was performed, the recurrence risk
by gelfoam itself in previously embolized vessels was low,
Bronchial Artery Embolic Agents versus Effectiveness
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Table 3. Initial Success Rate and Short- and Mid-term
Results Among Groups
Group 1  Group 2 Group 3
(n = 74) (n = 205) (n = 151)      
Technical success (%) 85 (63) 85 (175) 90 (136)
Clinical success (%) 72 (53) 74 (152) 71 (107)
Mid-term result (%)
� 45 (33) 63 (130) 62 (94)0
Note.─
�In mid-term results of each group, two patients in group 1, three 
patients in group 2, and two patients in group 3 had recurrences from
collateral blood flow.
Fig. 2. Cumulative hemoptysis-free rates for each group.
Agent
gelfoam
PVA(355-
500 μ m)
PVA(500-
710 μ m)Hahn et al.
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and hence there was no definite difference with other
results, despite gelfoam being more absorbable in theory.
Some authors also reported that there was no difference in
the success rates among the various embolic agents (14,
18), and no difference in the results was noted among
gelfoam and other non-absorbable agents (18). However in
this study, under similar underlying disease conditions,
technical failure, and the same follow-up period, we
presented that PVA is superior for long-term outcomes in
BAE, especially with the comparison among the mid-term
results (except for the recurrence from collateral vessels),
and provided a buttress for PVA in previous arguments
about embolic efficacy.
The reason to establish a follow-up period to 12 months
is to minimize the recurrence from collateral vessels.
According to the report by Tanaka et al. (13), causes of
recurrent hemoptysis include recanalization and reperfu-
sion. Reperfusion is achieved by newly developed collat-
eral vessels as underlying diseases progress with time (17).
Thus, in our study, we set a follow-up period of 12 months
to have a minimal impact on the recurrence risk from
collateral vessels due to underlying diseases.
Many factors affected these results; because of the
gelfoam particle’s good absorbability, previously
embolized vessels can recanalize earlier than in the case of
PVA embolization. Therefore, rebleeding risk can increase
with time. Also, the larger size of the gelfoam particles
compared to PVA cannot occlude bleeding at the small
arteriole level (16). 
This study has several limitations. First, the maximum
follow-up period was 12 months. Second, it was a
retrospective analysis of patients from a single center.
Finally, we did not compare the results to newer embolic
materials such as embosphere, bead block, hepasphere,
and others.
In conclusion, PVA is a better choice than gelfoam
particle for BAE to improve the result, and it is considered
that the material size of PVA needs to be selected to match
the vascular diameter.
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